Seres Therapeutics (NASDAQ:MCRB - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Seres Therapeutics to post earnings of ($0.17) per share for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.
Seres Therapeutics Stock Up 4.1 %
NASDAQ MCRB traded up $0.03 on Friday, reaching $0.77. The company had a trading volume of 503,791 shares, compared to its average volume of 1,456,032. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $1.53. The stock has a market capitalization of $133.28 million, a P/E ratio of -3.33 and a beta of 2.19. The company's fifty day moving average is $0.81 and its 200 day moving average is $0.84.
Analysts Set New Price Targets
MCRB has been the subject of several research analyst reports. Chardan Capital reaffirmed a "buy" rating and set a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, November 13th. StockNews.com raised Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $10.00 target price on shares of Seres Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $5.08.
Get Our Latest Stock Analysis on Seres Therapeutics
Seres Therapeutics Company Profile
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
See Also
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
